Free Trial
→ Stranded On The Flood Plains of History (From Porter & Company) (Ad)tc pixel
NASDAQ:VTGN

VistaGen Therapeutics Q4 2026 Earnings Report

VistaGen Therapeutics logo
$0.54 -0.01 (-1.23%)
Closing price 04:00 PM Eastern
Extended Trading
$0.54 +0.00 (+0.15%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

VistaGen Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.34
Beat/Miss
N/A
One Year Ago EPS
N/A

VistaGen Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.40 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

VistaGen Therapeutics Announcement Details

Quarter
Q4 2026
Date
7/1/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

VistaGen Therapeutics Earnings Headlines

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
June 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519798012/en/vistagen-appoints-angel-s.-angelov-md-mba-as-chief-medical-officer/
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.tc pixel
June 8 at 1:00 AM  |  Brownstone Research (Ad)
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
May 19, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-vistagen-therapeutics-inc-vtgn-a-breakout-anxiety-drug-stock-after-new-phase-3-extension-results-1764536/
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512521110/en/Vistagen-Announces-Preliminary-Positive-Data-in-Ongoing-Open-Label-Extension-Portion-of-PALISADE-3-Phase-3-Study-of-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder/
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
May 8, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260508181101/en/Vistagen-Announces-Completion-of-Last-Patient-Visit-in-PALISADE-4-Phase-3-Public-Speaking-Challenge-Study-of-Fasedienol-for-Acute-Treatment-of-Social-Anxiety-Disorder/
See More VistaGen Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VistaGen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VistaGen Therapeutics and other key companies, straight to your email.

About VistaGen Therapeutics

VistaGen Therapeutics (NASDAQ:VTGN) (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia.

VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.

View VistaGen Therapeutics Profile
Earnings Tools